The poster presentation, at the 29th Annual Meeting of the American Society for Bone and Mineral Research in Honolulu, Hawaii, was entitled “Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation, PTH and Bisphosphonate Therapy.” The data illustrated that the technology promotes rapid, targeted new bone formation within the thigh bone of an animal that can be maintained for an extended period of time by treatment with a bone building agent, such as PTH, followed by a commonly used bone protective agent, such as a bisphosphonate.
Warren Levy, president and CEO of Unigene, said: “Although still in the early stages of development, we continue to believe that this technology could represent an important breakthrough in the prevention and treatment of certain commonplace but serious bone-related medical conditions. There is an important unmet need for a rapid, minimally-invasive procedure to strengthen specific bones that are at risk of fracture, or to accelerate fracture repair.”